



Attorney's Docket No.: 12071-014001

#14/a  
Harry  
Oct 20, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mizzen *et al.*

Art Unit : 1645

Serial No. : 09/001,737

Examiner : Iesha Fields

Filed : December 31, 1997

Title : STREPTOCOCCAL HEAT SHOCK PROTEINS OF THE HSP60 FAMILY

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
OCT 19 2001  
TECH CENTER 1600/2900

RESPONSE AND REQUEST FOR INTERVIEW

In response to the Office action mailed April 10, 2001, please amend the application as follows.

In the claims:

Please amend claims 3, 4, 19, and 31 as follows.

a  
b  
7  
1

-- 3. An isolated nucleotide molecule selected from the group consisting of:

(a) an isolated nucleic acid molecule comprising the sequence of SEQ ID NO: 1 from nucleotides 15-1652;

(b) an isolated nucleic acid molecule comprising the sequence of SEQ ID NO: 3 from nucleotides 15-1640;

(c) an isolated nucleic acid molecule comprising the sequence of SEQ ID NO: 5 from nucleotides 15-1649;

(d) an isolated nucleic acid molecule comprising the sequence of SEQ ID NO: 7 from nucleotides 15-1652; and

(e) an isolated nucleic acid molecule complementary to any one of the nucleotides of SEQ ID NOS: 1, 3, 5 or 7 set forth in (a) through (d), respectively.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

October 10, 2001  
Date of Deposit

Lisa G. Gray  
Signature

Lisa G. Gray  
Typed or Printed Name of Person Signing Certificate

4. An isolated nucleic acid molecule comprising at least 24 nucleotides that specifically hybridizes to the nucleic acid molecule of any one of SEQ ID NO: 1 from nucleotides 15-1652, SEQ ID NO: 3 from nucleotides 15-1640, SEQ ID NO: 5 from nucleotides 15-1649, or SEQ ID NO: 7 from nucleotides 15-1652 or a complement thereof under conditions of high stringency.

---

19. A vector comprising an isolated nucleic acid molecule according to any one of claims 2-8.

---

31. A composition comprising an isolated nucleic acid molecule of any one of claims 2-8 and a pharmaceutically acceptable carrier or diluent.--

---